IRIS
AGUSTONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 989
AS - Asia 902
EU - Europa 721
SA - Sud America 156
AF - Africa 28
OC - Oceania 1
Totale 2.797
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 932
SG - Singapore 298
CN - Cina 254
HK - Hong Kong 189
RU - Federazione Russa 177
IT - Italia 153
BR - Brasile 122
DE - Germania 114
FI - Finlandia 73
VN - Vietnam 64
GB - Regno Unito 56
IE - Irlanda 37
CA - Canada 33
IN - India 31
PL - Polonia 20
FR - Francia 18
MX - Messico 18
ZA - Sudafrica 17
JP - Giappone 15
NL - Olanda 13
AR - Argentina 12
AT - Austria 12
BD - Bangladesh 12
ES - Italia 11
CZ - Repubblica Ceca 10
SE - Svezia 10
VE - Venezuela 7
SA - Arabia Saudita 6
TR - Turchia 5
BE - Belgio 4
CO - Colombia 4
EC - Ecuador 4
IQ - Iraq 4
KG - Kirghizistan 4
LT - Lituania 4
MA - Marocco 4
KE - Kenya 3
PK - Pakistan 3
CL - Cile 2
LV - Lettonia 2
PA - Panama 2
PT - Portogallo 2
PY - Paraguay 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
UA - Ucraina 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
GT - Guatemala 1
ID - Indonesia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
TJ - Tagikistan 1
YE - Yemen 1
Totale 2.797
Salva come PNG Salva come JPEG
Città #
Hong Kong 189
Dallas 176
Singapore 147
Ashburn 145
Beijing 79
Boardman 59
Munich 52
Los Angeles 49
New York 41
Shanghai 38
Redondo Beach 37
Turku 37
Dublin 36
Helsinki 36
Moscow 36
Milan 32
Ho Chi Minh City 23
Pavia 19
Warsaw 18
Falkenstein 16
Hanoi 16
São Paulo 16
Tokyo 15
Düsseldorf 14
Buffalo 13
Chennai 12
The Dalles 12
Toronto 12
Frankfurt am Main 11
London 11
Rome 11
Seattle 11
Montreal 10
Stockholm 10
Boston 9
Brooklyn 9
Guangzhou 9
Johannesburg 9
Nuremberg 9
Chicago 8
Columbus 8
Manchester 8
Mexico City 8
Phoenix 8
Santa Clara 8
Brno 7
Cesena 7
Hyderabad 7
Orem 7
Elk Grove Village 6
Palermo 6
Querétaro 6
Atlanta 5
Denver 5
Poplar 5
Rio de Janeiro 5
Vancouver 5
Vienna 5
Ankara 4
Bishkek 4
Bondo 4
Changsha 4
Houston 4
Washington 4
Belo Horizonte 3
Buenos Aires 3
Desio 3
Florence 3
Hải Dương 3
Jacksonville 3
Maastricht 3
Nairobi 3
Quito 3
San Francisco 3
Tianjin 3
'Asir Region 2
Agadir 2
Amsterdam 2
Bagnaria 2
Biassono 2
Brussels 2
Bắc Ninh 2
Calgary 2
Casatenovo 2
Castel del Giudice 2
Chandler 2
Dalian 2
Drexel Hill 2
Durban 2
Fernandópolis 2
Fortaleza 2
Groningen 2
Hortolândia 2
Jiaxing 2
Joinville 2
Karachi 2
L’Aquila 2
Maceió 2
Marília 2
Mauá 2
Totale 1.715
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 115
Smoking Habit and Respiratory Function Predict Patients' Outcome after Surgery for Lung Cancer, Irrespective of Histotype and Disease Stage 97
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 93
Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience 81
Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study 77
Correlation between PD-L1 Expression of Non-Small Cell Lung Cancer and Data from IVIM-DWI Acquired during Magnetic Resonance of the Thorax: Preliminary Results 77
Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center "Blue Sky Radiomics" study on stage III unresectable NSCLC 73
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study 72
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets 72
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer 71
Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI 70
From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers-A Multidisciplinary Perspective 69
Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study 69
CT Scan-Guided Fine Needle Aspiration Cytology for Lung Cancer Diagnosis through the COVID-19 Pandemic: What We Have Learned 68
Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach 66
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 62
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer 60
Phase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design 56
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) 54
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry 51
The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs 50
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling 50
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis 49
Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy? 48
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 47
Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan 47
Radiomics features as predictive and prognostic biomarkers in NSCLC 47
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 45
Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review 44
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC 43
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era 42
The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma 42
Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease 42
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer 41
The Clinical Value of Nutritional Care before and during Active Cancer Treatment 40
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 40
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 40
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 38
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines 36
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group 35
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program 34
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 34
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer 33
Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial 32
T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma 30
Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact 29
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients 29
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach 27
Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features 25
PACIFIC trial: new perspectives for immunotherapy in lung cancer 24
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy 24
Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story 22
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 22
Palonosetron Plus Dexamethasone in Highly Emetogenic Chemotherapy: Pooled Data from Two Phase III Trials 22
A non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination 22
Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer? Analysis of a Phase II Trial 22
Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial 18
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 17
Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies 16
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? 15
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations 14
Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders 14
Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem 14
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy 13
Totale 2.871
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.876
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.876
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 8 0 1 3 31 0 79 15
2023/2024343 40 46 29 27 31 69 31 15 0 18 6 31
2024/20251.096 40 45 33 22 11 123 54 62 260 84 121 241
2025/20261.295 203 149 241 315 310 77 0 0 0 0 0 0
Totale 2.871